US2019071688A1PendingUtilityA1

Compositions and methods for modifying genomes

Assignee: BENSON HILL BIOSYSTEMS INCPriority: Feb 15, 2016Filed: Sep 19, 2018Published: Mar 7, 2019
Est. expiryFeb 15, 2036(~9.5 yrs left)· nominal 20-yr term from priority
C12N 15/8202C12N 15/62C12N 15/8213C12N 15/8274C12N 9/22C12N 15/102C12N 15/8201C12N 2310/20C12N 15/113C12N 2800/22
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and/or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cpf1 or Csm1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided. Compositions comprise DNA constructs comprising a promoter that is operable in the cells of interest operably linked to nucleotide sequences that encode a mutated Cpf1 or Csm1 protein with an abolished ability to produce DSBs, optionally linked to a domain that regulates transcriptional activity. The methods can be used to up- or down-regulate the expression of genes at predetermined genomic loci.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of modifying a nucleotide sequence at a target site in the genome of a eukaryotic cell comprising:
 introducing into said eukaryotic cell
 (i) a DNA-targeting RNA, or a DNA polynucleotide encoding a DNA-targeting RNA, wherein the DNA-targeting RNA comprises: (a) a first segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA; and (b) a second segment that interacts with a Cpf1 or Cms1 polypeptide; and 
 (ii) a Cpf1 or Cms1 polypeptide, or a polynucleotide encoding a Cpf1 or Cms1 polypeptide, wherein the Cpf1 or Cms1 polypeptide comprises: (a) an RNA-binding portion that interacts with the DNA-targeting RNA; and (b) an activity portion that exhibits site-directed enzymatic activity, 
   
       wherein said Cpf1 or Cms1 polypeptide has at least 95% identity with a sequence selected from the group consisting of: SEQ ID NOs: 3, 6, 9, 12, 15, 18, 20, 23, 106-124, 126-132, 135-137, 139-141, 144-146, 148-159, 161-172, and 231-236, and has Cpf1 or Cms1 nuclease activity, wherein said method modifies said nucleotide sequence at said target site, and wherein said genome of a eukaryotic cell is a nuclear, plastid, or mitochondrial genome. 
     
     
         2 . A method of modifying a nucleotide sequence at a target site in the genome of a prokaryotic cell comprising:
 introducing into said prokaryotic cell
 (i) a DNA-targeting RNA, or a DNA polynucleotide encoding a DNA-targeting RNA, wherein the DNA-targeting RNA comprises: (a) a first segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA; and (b) a second segment that interacts with a Cpf1 or Cms1 polypeptide; and 
 (ii) a Cpf1 or Cms1 polypeptide, or a polynucleotide encoding a Cpf1 or Cms1 polypeptide, wherein the Cpf1 or Cms1 polypeptide comprises: (a) an RNA-binding portion that interacts with the DNA-targeting RNA; and (b) an activity portion that exhibits site-directed enzymatic activity, 
   
       wherein said Cpf1 or Cms1 polypeptide has at least 95% identity with a sequence selected from the group consisting of: SEQ ID NOs: 3, 6, 9, 12, 15, 18, 20, 23, 106-124, 126-132, 135-137, 139-141, 144-146, 148-159, 161-172, and 231-236, and has Cpf1 nuclease activity, wherein said method modifies said nucleotide sequence at said target site, wherein said genome of a prokaryotic cell is a chromosomal, plasmid, or other intracellular DNA sequence, and wherein said prokaryotic cell is not the natural host of a gene encoding said Cpf1 polypeptide. 
     
     
         3 . The method of  claim 1  wherein said eukaryotic cell is a plant cell. 
     
     
         4 . The method of  claim 1 , wherein said Cpf1 or Cms1 polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs: 3, 6, 9, 12, 15, 18, 20, 23, 106-124, 126-132, 135-137, 139-141, 144-146, 148-159, 161-172, and 231-236. 
     
     
         5 . The method of  claim 2 , wherein said Cpf1 or Cms1 polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs: 3, 6, 9, 12, 15, 18, 20, 23, 106-124, 126-132, 135-137, 139-141, 144-146, 148-159, 161-172, and 231-236. 
     
     
         6 . The method of  claim 1 , wherein said modified nucleotide sequence comprises insertion of heterologous DNA into the genome of the cell, deletion of a nucleotide sequence from the genome of the cell, or mutation of at least one nucleotide in the genome of the cell. 
     
     
         7 . The method of  claim 2 , wherein said modified nucleotide sequence comprises insertion of heterologous DNA into the genome of the cell, deletion of a nucleotide sequence from the genome of the cell, or mutation of at least one nucleotide in the genome of the cell. 
     
     
         8 . The method of  claim 1  wherein said modified nucleotide sequence comprises insertion of a polynucleotide that encodes a protein conferring antibiotic or herbicide tolerance to transformed cells. 
     
     
         9 . A nucleic acid molecule comprising a polynucleotide sequence encoding a Cpf1 or Cms1 polypeptide, wherein said polynucleotide sequence has at least 95% identity with a sequence selected from the group consisting of SEQ ID NOs: 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 21, 22, 24, 25, 174, 177, 178, 180-184, 187, 188, 190, 192, 194-204, and 206, or a fragment or variant thereof, or wherein said polynucleotide sequence encodes a Cpf1 or Cms1 polypeptide with at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 3, 6, 9, 12, 15, 18, 20, 23, 106-124, 126-132, 135-137, 139-141, 144-146, 148-159, 161-172, and 231-236, and has Cpf1 or Cms1 nuclease activity, and wherein said polynucleotide sequence encoding a Cpf1 or Cms1 polypeptide is operably linked to a promoter that is heterologous to the polynucleotide sequence encoding a Cpf1 or Cms1 polypeptide. 
     
     
         10 . The nucleic acid molecule of  claim 9  wherein said nucleic acid molecule comprising a polynucleotide sequence encoding a Cpf1 or Cms1 polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs: 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 21, 22, 24, 25, 174, 177, 178, 180-184, 187, 188, 190, 192, 194-204, and 206 or encodes a Cpf1 or Cms1 polypeptide that comprises a sequence selected from the group consisting of SEQ ID NOs: 3, 6, 9, 12, 15, 18, 20, 23, 106-124, 126-132, 135-137, 139-141, 144-146, 148-159, 161-172, and 231-236. 
     
     
         11 . A plant cell, eukaryotic cell, or prokaryotic cell comprising the nucleic acid molecule of  claim 9 . 
     
     
         12 . A plant cell, eukaryotic cell, or prokaryotic cell comprising the nucleic acid molecule of  claim 10 . 
     
     
         13 . A eukaryotic cell produced by the method of  claim 1 . 
     
     
         14 . The eukaryotic cell of  claim 13  wherein said eukaryotic cell is a plant cell. 
     
     
         15 . A plant comprising the nucleic acid molecule of  claim 9 . 
     
     
         16 . A plant comprising the nucleic acid molecule of  claim 10 . 
     
     
         17 . A plant produced by the method of  claim 3 . 
     
     
         18 . The seed of the plant of  claim 15 . 
     
     
         19 . The seed of the plant of  claim 17 . 
     
     
         20 . The nucleic acid molecule of  claim 9  wherein said polynucleotide sequence encoding a Cpf1 or Cms1 polypeptide is codon-optimized for expression in a plant cell.

Join the waitlist — get patent alerts

Track US2019071688A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.